ClinicalTrials.gg
CompletedNCT03758469Updated Aug 20, 2019

A Study Evaluating Drug-Drug Interaction (DDI) Between HSK3486 Injectable Emulsion and Rifampin Capsules

A Phase 1 interventional study of HSK3486 and rifampin , HSK3486 in Anesthesia and Sedation, sponsored by Sichuan Haisco Pharmaceutical Group Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-08-20.

Sponsored by Sichuan Haisco Pharmaceutical Group Co., Ltd (part of Haisco Pharmaceutical Group Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a Phase I, single-center, open-label, randomized,two-way crossover, propofol-controlled, two-stage study evaluating the safety and pharmacokinetics/pharmacodynamics of IV maintenance dose and IV single loade dose plus maintenance dose of HSK3486 emulsion for injection in healthy subjects.

02

Conditions studied

  • Anesthesia
  • Sedation
03

In context

Lead sponsor

Sichuan Haisco Pharmaceutical Group Co., Ltd is the lead sponsor of 30 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males or females with full capacity for civil conduct, aged ≥18 and ≤45 years old. Both male and female subjects should be enrolled;
  2. Male subjects weighing ≥50 kg, female subjects weighing ≥45 kg. All subjects should have a (BMI) of ≥19.0 and ≤26.0 kg/m2;
  3. Blood pressure between 100-139/60-89 mmHg; heart rate between 60-99 beats/min; body temperature between 35.8-37.5 °C; respiratory rate between 12-20 breaths/min; SpO2 when inhaling ≥95%;
  4. Normal physical examinations, laboratory examinations (blood routine, blood biochemistry and urine routine), and 12-lead (ECG), or abnormal but without clinical significance as judged by the investigators; no significantly potential difficult airway (modified Mallampati score I-II);
  5. No previous history of major organ primary diseases, such as liver, kidneys, digestive tract, blood, and metabolic diseases; no history of malignant hyperthermia and other genetic conditions; no history of mental/neurological diseases; no history of epilepsy; no for deep sedation/general anesthesia; no history of anesthesia accidents;
  6. Subjects must understand the procedures and methods of this study, and be willing to provide and to complete the trial in strict accordance with trial protocol.

Exclusion criteria

Exclusion Criteria:

  1. Known sensitivity to in HSK3486 injectable emulsion (soybean oil, glycerin, triglyceride, egg lecithin, sodium oleate and sodium hydroxide), rifampin, or mentioned in the prescribing information of rifampin; history of drug allergies (including anesthetics), allergic diseases, or those with hyperactive immune response;
  2. In receipt of any one of the following medications or treatments during screening/baseline:

    1. History of drug abuse or any signs of chronic benzodiazepines use (such as insomnia, anxiety, spasms) within 3 months prior to screening, or a positive urine drug test during baseline;
    2. Participated in clinical trials involving any medications or medical devices within 3 months prior to screening, or subjects who have participated in 3 or more drug clinical trials within the past year;
    3. In receipt of rifampin within 4 weeks prior to screening;
    4. Serious infection, trauma or major surgery within 4 weeks prior to screening; or acute disease with clinical significance (determined by the investigator) within 2 weeks prior to screening, including GI diseases or infections (such as respiratory or CNS infections);
    5. In receipt of propofol, other sedatives/anesthetics and/or opioid analgesics or compounds containing analgesics within 1 week prior to baseline;
    6. In receipt of prescription drugs, Chinese herbal medicines, over-the-counter drugs or food supplements (such as vitamins and calcium supplements) other than , paracetamol, oral non-steroidal anti-inflammatory drugs, topical over-the-counter preparations, within 2 weeks prior to baseline; unless the principal investigator (PI) and the sponsor agree that the medication has no effect on the safety and PK/PD results of the trial;
  3. A history or evidence of any one of the following diseases prior to screening/baseline:

    1. History of cardiovascular diseases such as: postural hypotension, severe arrhythmia, heart failure, Adams-Stokes syndrome, unstable angina, myocardial infarction within 6 months before screening, tachycardia/bradycardia requiring medication, third-degree atrioventricular block or interval ≥450 ms (Fridericia's correction formula);
    2. Respiratory insufficiency, history of obstructive pulmonary disease, history of asthma, sleep apnea; history of failed tracheal intubation; history of bronchospasm requiring treatment within 3 months prior to screening; acute respiratory infection, and with obvious symptoms such as fever, wheezing, nasal congestion or cough within 1 week prior to baseline;
    3. History of GI tract diseases: Gastrointestinal obstruction, active GI bleed, potential for reflux and aspiration;
  4. Laboratory results that meet any of the following during screening/baseline:

    1. Positive result for either , , , or syphilis;
    2. Abnormal hepatic or renal function confirmed after re-examination;

      • or AST > 1×;
      • Creatinine > 1×ULN;
      • > 1.0×ULN;
  5. History of alcohol abuse within 3 months prior to screening, abuse defined as average of > 2 units of alcohol per day (1 unit = 360 mL beer or 45 mL liquor with 40% alcohol or 150 mL wine), or positive result for breath alcohol test during baseline;
  6. Smoke more than 5 cigarettes per day and a total of more than 60 cigarettes within 3 months prior to screening;
  7. Blood donation or blood loss ≥200 mL within 30 days prior to screening; plasma donation or plasma exchange within 7 days prior to screening;
  8. Subjects who consume any beverages or foods containing alcohol, grapefruit juice or methylxanthine (such as coffee, tea, coca-cola, chocolate, functional drinks), to participate in strenuous physical activities and other factors that may affect drug absorption, distribution, metabolism, and excretion within 2 days prior to enrollment; subjects who are unable to fast for 8 hours prior to dose administration;
  9. Subjects expected to have surgery or hospitalization during the trial;
  10. Subjects unsuitable for arterial blood collection, such as subjects who have positive Allen's test;
  11. Women who are pregnant or breastfeeding; women of or men who are unwilling to use contraception during the trial; subjects who are planning pregnancy within 1 month after the completion of the trial (including male subjects);
  12. Subjects judged by the investigator to be unsuitable for participating in this trial for any reason.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    HSK3486

    0.4 mg/kg

    Drug: HSK3486

  • Experimental
    rifampin , HSK3486

    600 mg;0.4 mg/kg

    Drug: rifampin , HSK3486

Interventions

  • Sequence 1: Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.

  • Drugrifampin , HSK3486

    Drug pages: Rifampin · Ciprofol

    Sequence 2: Orally take 600 mg rifampin once a day for 8 consecutive days in the morning on an empty stomach, followed by 1 min intravenous infusion of 0.4 mg/kg HSK3486 30 min later.

06

What researchers measure

Primary outcomes

  1. Peak concentration (Cmax)

    Time frame: From the start of HSK3486 administration to 24 h after the start of administration on day 1

  2. Area under the concentration-time curve (AUC0-t, AUC0-∞)

    Time frame: From the start of HSK3486 administration to 24 h after the start of administration on day 1

Secondary outcomes

  1. Terminal elimination half life (t1/2)

    Time frame: From the start of HSK3486 administration to 24 h after the start of administration on day 1

  2. Time to fully awake

    Time frame: From the start of HSK3486 administration until the subjects is fully awake on day 1

  3. MOAA/S(modified observer's assessment of alert /sedation)-time curve

    Observe the change of modified observer's assessment of alert /sedation during the whole trial

    Time frame: From the start of HSK3486 administration until the subjects is fully awake on day 1

  4. BIS(bispectral index)-time curve

    Observe the changes of bispectral index during the whole trial

    Time frame: From the start of HSK3486 administration to 60 min after the start of administration on day 1

  5. Blood pressure

    Observe the changes of blood pressure during the whole trial

    Time frame: From the start of HSK3486 administration to 24 h after the start of administration on day 1

  6. Heart rate

    Observe the changes of heart rate during the whole trial

    Time frame: From the start of HSK3486 administration to 24 h after the start of administration on day 1

  7. Respiratory rate or blood oxygen saturation

    Observe the changes of respiratory rate or blood oxygen saturation during the whole trial

    Time frame: From the start of HSK3486 administration to 24 h after the start of administration on day 1

  8. Blood routine test

    Observe the changes of blood routine test during the whole trial

    Time frame: From the start of HSK3486 administration to 24 h after the start of administration on day 1

  9. Urine routine test

    Observe the changes of urine routine test during the whole trial

    Time frame: From the start of HSK3486 administration to 24 h after the start of administration on day 1

  10. Blood biochemical examination

    Observe the changes of Blood biochemical examination during the whole trial

    Time frame: From the start of HSK3486 administration to 24 h after the start of administration on day 1

  11. 12-Electrocardiogram

    Observe the changes of heart rate, RR interval, QT interval , QTcF interval , PR interval and QRS interval of electrocardiogram during the whole trial

    Time frame: From the start of HSK3486 administration to 24 h after the start of administration on day 1

  12. Number of patients with adverse events

    Safety endpoits

    Time frame: From the start of HSK3486 administration to 24 h after the start of administration on day 1

  13. Concurrent medications

    Safety endpoits

    Time frame: From the start of HSK3486 administration to 24 h after the start of administration on day 1

07

Study locations

1 site
  • Shanghai Public Health Clinical Center
    Shanghai, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2018 to primary completion in Jan 2019, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2018
First posted
Nov 29, 2018
StartActual
Dec 14, 2018
Primary completionActual
Jan 31, 2019
CompletionActual
Mar 10, 2019
Last update
Aug 20, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03758469
Responsible party
Sponsor
First posted
Nov 29, 2018
Start date
Dec 14, 2018
Primary completion
Jan 31, 2019
Completion
Mar 10, 2019
Last update
Aug 20, 2019

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ciprofol · Rifampin

Start the discussion